Showing results (31-40 of 71) with videos related to
Sort By:
Pageof 8
Cancer Biotherapy & Radiopharmaceuticals|September 6, 2008
Slow dynamic lymphoscintigraphy is not a reliable predictor of sentinel-node negativity in cutaneous melanomaMarie-Elisabeth Toubert, Pierre-Alexandre Just, Georges Baillet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAF -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.Pigment Cell & Melanoma Research|July 5, 2019
Discoidin domain receptors: A promising target in melanomaCoralie Reger de Moura, Maxime Battistella, Anjum Sohail, et al.Journal for Immunotherapy of Cancer|April 10, 2020
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access programJohn W Walker, Celeste Lebbé, Giovanni Grignani, et al.Oncotarget|October 27, 2014
A novel tumor suppressor function of Kindlin-3 in solid cancerIbtissem Djaafri, Farah Khayati, Suzanne Menashi, et al.Transplantation|January 27, 2023
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical ManagementCarla Ferrándiz-Pulido, Ulrike Leiter, Catherine Harwood, et al.Acta Dermato-Venereologica|April 13, 2018
Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Series of 37 Cases and Systematic Review of the LiteratureRaphael Lhote, Jérôme Lambert, Julie Lejeune, et al.Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.The Lancet. Oncology|December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyJedd D Wolchok, Bart Neyns, Gerald Linette, et al.Pageof 8